|Day Low/High||31.88 / 32.55|
|52 Wk Low/High||31.54 / 47.82|
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD
These are just a few of the names I expect to do well to close out 2018.
These are a few of the names I expect to do well to close out 2018.
HERTFORDSHIRE, England and PITTSBURGH and SYDNEY, Sept. 24, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.
HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Sept. 21, 2018 /PRNewswire/ -- Mylan N.
- Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis -
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, Sept. 20, 2018 /PRNewswire/ -- Mylan N.
Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®)
- Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate -
Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD
The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.
- Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability -
Stocks ended mixed on Wednesday as a push from strong corporate earnings is muted by continued trade tensions between the U.S. and China.
The drugmaker 's board said the U.S. public markets 'continue to underappreciate and undervalue' the company's diversified business.
HERTFORDSHIRE, England, Aug. 8, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.
HERTFORDSHIRE, England and PITTSBURGH, Aug. 8, 2018 /PRNewswire/ -- Mylan N.
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
HERTFORDSHIRE, England, and PITTSBURGH, July 31, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.
HERTFORDSHIRE, England and PITTSBURGH, and TOKYO, July 27, 2018 /PRNewswire/ -- Mylan N.
The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
U.S. Court of Appeals for the Federal Circuit rejects Allergan's attempt to use tribal sovereign immunity to avoid Restasis® patent challenge
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
- The launch of Rivastigmine Transdermal System highlights Mylan's continued investment in difficult-to-manufacture products -
On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.
Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 /PRNewswire/ -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.
Despite a growing trade war between the U.S, and China, drug officials in that country have pledged to try to stop the flow of fentanyl into the U.S.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.